| EGFR和ErbB2双重酪氨酸激酶 |
| |
| 引用本文： | 封宇飞，曾春兰. EGFR和ErbB2双重酪氨酸激酶[J]. 中国新药杂志, 2007, 16(23): 1990-1993 |
| |
| 作者姓名： | 封宇飞，曾春兰 |
| |
| 作者单位： | 卫生部北京医院药学部临床药理室 北京100730(封宇飞)，广西工业职业技术学院 南宁530001(曾春兰) |
| |
| 摘 要： | 拉帕替尼是一种人源2型表皮生长因子受体(HER2)和表皮生长因子受体(EGFR)双重酪氨酸激酶抑制剂,与卡培他滨联用治疗女性HER2阳性的乳腺癌。我们利用MEDLINE进行关键词为拉帕替尼的文献检索,对其药理作用、药动学、临床疗效及安全性,药物相互作用等进行综述。
|
| 关 键 词： | 拉帕替尼二甲苯磺酸酯 酪氨酸激酶抑制剂 乳腺癌 |
| 文章编号： | 1003-3734（2007）23-1990-04 |
| 收稿时间： | 2007-08-14 |
| 修稿时间： | 2007-08-14 |
Advance in research for lapatinib, a dual inhibitor of EGFR and ErbB2 tyrosine kinase activity |
| |
| FENG Yu-fei ,ZENG Chun-lan. Advance in research for lapatinib, a dual inhibitor of EGFR and ErbB2 tyrosine kinase activity[J]. Chinese Journal of New Drugs, 2007, 16(23): 1990-1993 |
| |
| Authors: | FENG Yu-fei ZENG Chun-lan |
| |
| Abstract: | Lapatinib is a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2(HER2 or HER2/neu) and epidermal growth factor receptor(EGFR).It is active in combination with capecitabine in treatment of women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.A literature search was conducted by MEDLINE using the keyword lapatinib.Its pharmacology,pharmacokinetics,efficacy,safety and drug interactions in the treatment of breast cancer are reviewed in this paper. |
| |
| Keywords: | lapatinib ditosylate tyrosine kinase inhibitor breast cancer |
| 本文献已被 CNKI 维普 等数据库收录！ |
| 点击此处可从《中国新药杂志》浏览原始摘要信息 |
